Ohcanbohtosat - G. Charpentier

Aiddostahte ozu
  1. 1
    Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

    Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus Dahkki André Scheen, G. Charpentier, Carl Johan Östgren, Åsa Hellqvist, Ingrid Gause‐Nilsson

    Almmustuhtton 2010
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

    Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-M... Dahkki Coralie Amadou, Sylvia Franc, Pierre‐Yves Benhamou, Sandrine Lablanche, Erik Huneker, G. Charpentier, A. Penfornis

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    One‐year real‐world performance of the <scp>DBLG1</scp> closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany

    One‐year real‐world performance of the <scp>DBLG1</scp> closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany Dahkki Pierre‐Yves Benhamou, Alice Adenis, Hocine Lebbad, Yousra Tourki, Maria‐Belen Heredia, Bernhard Gehr, Sylvia Franc, G. Charpentier

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Implication of the Pro12Ala polymorphism of the PPAR-gamma 2gene in type 2 diabetes and obesity in the French population

    Implication of the Pro12Ala polymorphism of the PPAR-gamma 2gene in type 2 diabetes and obesity in the French population Dahkki Maya Ghoussaini, Stephen Eyre, Stéphane Lobbens, G. Charpentier, Karine Clément, Marie‐Aline Charles, M. Tauber, Jacques Weill, Philippe Froguel

    Almmustuhtton 2005
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

    Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials Dahkki Bo Åhrén, Stephen L. Atkin, G. Charpentier, Mark Warren, John Wilding, Stephen Birch, Anders G. Holst, Lawrence A. Leiter

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies

    The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies Dahkki Stéphane Cauchi, Kevin T. Nead, Hélène Choquet, Fritz Horber, Natascha Potoczna, Beverley Balkau, Michel Marre, G. Charpentier, Philippe Froguel, David Meyre

    Almmustuhtton 2008
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

    Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial Dahkki Andrew Ahmann, Matthew Capehorn, G. Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G. Holst, Miriam Annett, Vanita R. Aroda

    Almmustuhtton 2017
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Efficacy of a Hybrid Closed-Loop Solution in Patients With Excessive Time in Hypoglycaemia: A Post Hoc Analysis of Trials With DBLG1 System

    Efficacy of a Hybrid Closed-Loop Solution in Patients With Excessive Time in Hypoglycaemia: A Post Hoc Analysis of Trials With DBLG1 System Dahkki Pierre‐Yves Benhamou, Alice Adenis, Yousra Tourki, Sylvie Pou, Stéphanie Madrolle, Sylvia Franc, Dulanjalee Kariyawasam, Jacques Beltrand, David C. Klonoff, G. Charpentier

    Almmustuhtton 2022
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Genetic Analysis of <i>ADIPOR1</i> and <i>ADIPOR2</i> Candidate Polymorphisms for Type 2 Diabetes in the Caucasian Population

    Genetic Analysis of <i>ADIPOR1</i> and <i>ADIPOR2</i> Candidate Polymorphisms for Type 2 Diabetes in the Caucasian Population Dahkki Martine Vaxillaire, Aurélie Dechaume, Valérie Vasseur-Delannoy, Saida Lahmidi, Vincent Vatin, Frédéric Leprêtre, Philippe Boutin, Serge Herçberg, G. Charpentier, Christian Dina, Philippe Froguel

    Almmustuhtton 2006
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Hospital stays and costs of telemedical monitoring versus standard follow-up for diabetic foot ulcer: an open-label randomised controlled study

    Hospital stays and costs of telemedical monitoring versus standard follow-up for diabetic foot ulcer: an open-label randomised controlled study Dahkki Dured Dardari, Sylvia Franc, G. Charpentier, L. Orlando, Elise Bobony, Marie Bouly, I. Xhaard, Zohra Amrous, Khadijatou Ly Sall, B. Detournay, A. Penfornis

    Almmustuhtton 2023
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

    Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Dahkki John Wilding, G. Charpentier, Priscilla Hollander, Guillermo González-Gálvez, Chantal Mathieu, Frank Vercruysse, Keith Usiskin, Ga‐Lai Law, Simon Black, William Canovatchel, Gary Meininger

    Almmustuhtton 2013
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    Impact of Common Type 2 Diabetes Risk Polymorphisms in the DESIR Prospective Study

    Impact of Common Type 2 Diabetes Risk Polymorphisms in the DESIR Prospective Study Dahkki Martine Vaxillaire, J Veslot, Christian Dina, Christine Proença, Stéphane Cauchi, G. Charpentier, Jean Tichet, Frédéric Fumeron, Michel Marre, David Meyre, Beverley Balkau, Philippe Froguel

    Almmustuhtton 2007
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system

    Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system Dahkki Jean‐Pierre Riveline, J. Teynié, S. Belmouaz, Sylvia Franc, Dured Dardari, Marc Bauwens, Valérie Caudwell, Stéphanie Ragot, Frank Bridoux, G. Charpentier, R. Maréchaud, Samy Hadjadj

    Almmustuhtton 2009
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Ketosis-Prone Type 2 Diabetes in Patients of Sub-Saharan African Origin

    Ketosis-Prone Type 2 Diabetes in Patients of Sub-Saharan African Origin Dahkki Franck Mauvais‐Jarvis, Eugène Sobngwi, Raphaël Porcher, Jean‐Pierre Riveline, Jean-Philippe Kévorkian, Christian Vaisse, G. Charpentier, Pierre-Jean Guillausseau, Patrick Vexiau, Jean‐François Gautier

    Almmustuhtton 2004
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Quality of Care of People With Type 2 Diabetes in Eight European Countries

    Quality of Care of People With Type 2 Diabetes in Eight European Countries Dahkki Margaret Stone, G. Charpentier, Kris Doggen, Oliver Kuß, Ulf Lindblad, Christiane Kellner, John J. Nolan, Agnieszka Pazderska, Guy E.H.M. Rutten, Marina Trento, Kamlesh Khunti

    Almmustuhtton 2013
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    Insulin Infusion Set Use: European Perspectives and Recommendations

    Insulin Infusion Set Use: European Perspectives and Recommendations Dahkki Dorothee Deiss, Peter Adolfsson, Marije Alkemade-van Zomeren, Geremia B. Bolli, G. Charpentier, Claudio Cobelli, Thomas Danne, A. Girelli, Heiko Mueller, Carol A. Verderese, Éric Renard

    Almmustuhtton 2016
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    Insulin‐based strategies to prevent hypoglycaemia during and after exercise in adult patients with type 1 diabetes on pump therapy: the <scp>DIABRASPORT</scp> randomized study

    Insulin‐based strategies to prevent hypoglycaemia during and after exercise in adult patients with type 1 diabetes on pump therapy: the <scp>DIABRASPORT</scp> randomized study Dahkki Sylvia Franc, A. Daoudi, A. Pochat, M. Petit, Caroline Randazzo, C. Petit, Martine Duclos, A. Penfornis, Eric Pussard, D. Not, Elsa Heyman, François Koukoui, Chantal Simon, G. Charpentier

    Almmustuhtton 2015
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA1c in Poorly Controlled Type 1 Diabetic Patients

    The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA1c in Poorly Controlled Type 1 Diabetic Patients Dahkki G. Charpentier, Pierre‐Yves Benhamou, Dured Dardari, Annie Clergeot, Sylvia Franc, P Schaepelynck-Bélicar, Bogdan Catargi, V. Melki, Lucy Chaillous, Anne Farret, Jean‐Luc Bosson, A. Penfornis

    Almmustuhtton 2011
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    Transcription Factor <i>TCF7L2</i> Genetic Study in the French Population

    Transcription Factor <i>TCF7L2</i> Genetic Study in the French Population Dahkki Stéphane Cauchi, Stephen Eyre, Christian Dina, Hélène Choquet, Chantal Samson, Sophie Gallina, Beverley Balkau, G. Charpentier, François Pattou, Volodymyr Stetsyuk, Raphaël Scharfmann, Bart Staels, Gema Frühbeck, Philippe Froguel

    Almmustuhtton 2006
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial

    Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial Dahkki Dulanjalee Kariyawasam, Carole Morin, Kristina Casteels, C. Le Tallec, Annie Sfez, Cécile Godot, Erik Huneker, Nathalie Garrec, Pierre‐Yves Benhamou, Michel Polak, G. Charpentier, Sylvia Franc, Jacques Beltrand

    Almmustuhtton 2022
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: